Prof Alberto Sobrero speaks to ecancer about results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration looking at three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients with stage III colon cancer presented at the ASCO virtual meeting 2020.
He explains that this is an international initiative looking at 13,000 stage III colon cancer patients over the course of 8 years.
Prof Sobrero reports that the main finding was that 6 months was not better than 3 months as seen by the overall survival.
He adds that things were made more complicated due to the predetermined non-inferiority margin for 5 year overall survival being just met.
Prof Sobrero states that while statistically the analysis had failed, common sense showed the identical nature of the two durations.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.